-
Budesonide
- indication:For the treatment of mild to moderate active Crohn's disease. Also for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.
- pharmacologypharmacology:
- mechanism: The exact mechanism of action of budesonide in the treatment of Crohn's disease is not fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect.
- toxicity: Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema.
- absorprion: Absorption is complete following oral administration.
- halflife: 2.0 and 3.6 hours
- roouteelimination: Budesonide is excreted in urine and feces in the form of metabolites.
- volumedistribution: * 3 L/kg [asthmatic children 4 to 6 years of age]
- clearance: * 0.5 L/min [Athmatic children 4 to 6 years of age]